Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 124 clinical trials
featured
Myelofibrosis

Myelofibrosis

  • 532 views
  • 08 Nov, 2020
  • 1 location
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC), and which will be elected by the Investigator prior to randomisation.

hydroxyurea
interferon
ruxolitinib
  • 0 views
  • 24 Jan, 2021
  • 2 locations
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.

hydroxyurea
platelet count
neutrophil count
interferon
thrombosis
  • 0 views
  • 20 Mar, 2021
  • 51 locations
Determining the Impact of Scaling up Mass Testing Treatment and Tracking on Malaria Prevalence in Ghana

Globally, malaria prevalence in 2016 was reported to have increased with 445,000 deaths, 91% of which occurred in sub-Sahara Africa with more than 75% being children. Individuals who carry the malaria parasite can either be symptomatic (showing signs and symptoms) or asymptomatic (without signs and symptoms). Asymptomatic malaria parasitaemia pose …

  • 14 views
  • 24 Jan, 2021
  • 1 location
Hepcidin Mimetic in Patients With Polycythemia Vera

and to obtain preliminary evidence of efficacy of PTG-300 for the treatment of phlebotomy-requiring polycythemia vera.

hydroxyurea
interferon
ruxolitinib
phlebotomy
  • 8 views
  • 26 Jan, 2021
  • 17 locations
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

This is an open label, single arm trial of PTG-300 in subjects with PV who are newly diagnosed or for whom current therapy is not sufficient to control their hematocrit and have hematocrit &gt

  • 0 views
  • 11 Mar, 2021
  • 5 locations
Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins

We conduct a randomized study comparing the safety and effectiveness of two interventional ablation techniques for treatment of paroxysmal atrial fibrillation: the segmental pulmonary vein ablation approach, (1) with empiric isolation of all pulmonary veins or (2) Segmental Isolation of the arrhythmogenic pulmonary vein(s)

paroxysmal atrial fibrillation
antiarrhythmic drug
  • 5 views
  • 07 Nov, 2020
  • 1 location
Mechanisms of Right Ventricular Adaptation in Patients With Heart Failure With Preserved Ejection Fraction

Biventricular PV-loop studies and advanced imaging to assess left-to-right ventricular interaction in HFpEF: In a group of 30 HFpEF patients with clinical indication for LH/RH catheter

heart failure with preserved ejection fraction
ejection fraction
medical therapy
  • 0 views
  • 25 Jan, 2021
  • 2 locations
Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation

Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation Diagnosis MF(includ Post-ET,Post-PV,PMF) With at least two month

  • 0 views
  • 26 Jan, 2021
  • 1 location
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

PRV-GD2-101 is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose PR001 in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the

type 1 gaucher disease
  • 0 views
  • 26 Jan, 2021
  • 4 locations